Leslie M. Shaw, Ph.D.
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Director, Alzheimer's Disease Neuroimaging, Initiative Biomarker Core Laboratory, University of Pennsylvania
Department: Pathology and Laboratory Medicine
Contact information
Hospital of the University of Pennsylvania
7.103 Founders Pavilion 3400 Spruce Street
Philadelphia, PA 19104
7.103 Founders Pavilion 3400 Spruce Street
Philadelphia, PA 19104
Office: (215) 662-6575
Fax: (215) 662-7529
Fax: (215) 662-7529
Education:
B.S. (Cum Laude, Chemistry)
LeMoyne College, Syracuse, New York, 1962.
Ph.D. (Biochemistry)
S.U.N.Y. at Upstate Medical Center, 1968.
Permanent linkB.S. (Cum Laude, Chemistry)
LeMoyne College, Syracuse, New York, 1962.
Ph.D. (Biochemistry)
S.U.N.Y. at Upstate Medical Center, 1968.
Description of Research Expertise
Development, validation and implementation of neurodegenerative diseases biomarkers in cerebrospinal fluid and plasma into treatment trials and clinical studies (eg, ADNI study; UPENN ADRC; PPMI study). These studies include the use of manual and highly automated immunoassays and for amyloid beta(1-42), U-p53AZ and for total tau the use of high sensitivity UPLC/tandem mass spectrometry. Multi-modal statistical analyses of these study data to address several questions including the diagnostic utilities of these biomarkers; assessments of the longitudinal trajectories of these biomarkers in AD, MCI and cognitively normal controls to assess the neuropathological changes over time in these individuals.Description of Clinical Expertise
Measurement and interpretation of the toxicokinetics of drugs and toxins in patients affected by them. Interpretation of the pharmacokinetics of immunosuppressant maintenance medications in transplant patients.Description of Other Expertise
Development and implementation of mass spectrometry-based methods for measuring small molecules of clinical utility including therapeutic drugs, toxins and special chemistry tests including Xylazine; 25-OH vitamin D; and biologicals, eg, Infliximab.Selected Publications
Shaw LM, Galasko D. : Assessments of the utilities of CSF NPTX2 for disease progression in cognitively normal individuals who progress to clinical MCI and AD. Ann Neurol Invited Commentary In Press, 2023, In Press.Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, Vellas B, O’Bryant S, Shaw LM, Cho M, Batrla R, Vergallo A, Blennow K, Dage J, Suzanne E. Schindler.: Blood-based biomarkers for Alzheimer’s disease: current state and future use in a transformed global healthcare landscape. Neuron. In Press, 2023 In Press.
Tropea TF, Waligorska T, Xie SX, Nasrallah IM, Cousins KAQ, Trojanowski JQ, Grossman M, Irwin DJ, Weintraub D, Lee EB, Wolk DA, Chen-Plotkin AS, Shaw LM; Alzheimer's Disease Neuroimaging Initiative. : Plasma phosphorylated tau181 predicts cognitive and functional decline. Ann Clin Transl Neurol. 10(1): 18-31, Jan. 2023 Notes: doi: 10.1002/acn3.51695. Epub 2022 Dec 14.
Brand AL, Lawler PE, Bollinger JG, Li Y, Schindler SE, Li M, Lopez SC, Ovod V, Nakamura A, Shaw LM, Zetterberg H, Hansson O, Bateman RJ.: The performance of plasma amyloid beta measurement in predicting amyloid burden: a literature review. Alzheimer's Res Ther. 14(1): 195, Dec 27 2022 Notes: doi: 10.1186/s13195-022-01117-1.
Cousins KAQ, Shaw LM, Shellikeri S, Dratch L, Rosario L, Elman LB, Quinn C, Amado DA, Wolk DA, Tropea TF, Chen-Plotkin A, Irwin DJ, Grossman M, Lee EB, Trojanowski JQ, McMillan CT. : Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis. Ann Neurol. 92(5): 807-818, Nov 2022 Notes: doi: 10.1002/ana.26462. Epub 2022, Aug 17.
Morris JC, Weiner M, Xiong C, Beckett L, Coble D, Saito N, Aisen PS , Allegri R, Benzinger TLS, Berman SB, Cairns NJ, Carrillo MC, Chui HC, Chhatwal JP, Cruchaga C, Fagan AM, Farlow M, Fox NC, Ghetti B, Goate AM, Gordon BA, Graff-Radford N, Day GS, Hassenstab J, Ikeuchi T, Jack CR Jr, Jagust WJ, Jucker M, Levin J, Massoumzadeh P, Masters CL, Martins R, McDade E, Mori H, Noble JM, Petersen RC, Ringman JM, Salloway S, Saykin AJ, Schofield PR, Shaw LM, Toga AW, Trojanowski JQ, Voglein J, Weninger S, Bateman RJ, Buckles VD, on behalf of the Dominantly Inherited Alzheimer Network (DIAN) and the Alzheimer's Disease Neuroimaging Initiative (ADNI).: Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology. Brain. 145(10): 3594-3607, Oct 2022 Notes: DOI: 10.1093/brain/awac181. PMID: 35580594.
Shaw LM, Vanderstichele H, Knapik-Czajka M, Blennow K, Trojanowski JQ. : Establishing an Autopsy-Based Cerebrospinal Fluid Biomarker Signature in Alzheimer Disease Patients. Clin Chem. 68(10): 1336-37, Oct 6 2022 Notes: doi: 10.1093/clinchem/hvac137.
Nilsson J, Cousins KAQ, Gobom J, Portelius E, Chen-Plotkin A, Shaw LM, Grossman M, Irwin DJ, Trojanowski JQ, Zetterberg H, Blennow K, Brinkmalm A. : Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders. Alzheimers Dement. Oct 14 2022 Notes: doi: 10.1002/alz.12809. Epub ahead of print. PMID: 36239248.
Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, Shaw LM, Masters CL, Fowler CJ, Trojanowski JQ, Korecka M, Martins RN, Janelidze S, Hansson O, Bateman RJ. : Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques. Neurology. 98(7), Feb. 15 2022 Notes: e688-e699. doi: 10.1212/WNL.0000000000013211. Epub 2021 Dec 14.
Zicha S, Bateman RJ, Shaw LM, Zetterberg H, Bannon AW, Horton WA, et al.: Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity. Alz Dementia 2022 Notes: DOI: 10.1002/alz.12697.